Introduction:
Pharmascience invests US$120 million to expand its sterile injectable manufacturing facility in Candiac site.
Features:
The facility aims to triple the current capacity, enabling it to serve a larger patient population by expanding its facilities and upgrading equipment with cutting-edge technology. Annual production is anticipated to surpass 20 million units as a result.
With a specialised focus on injectable products, the unit will prioritise offering CDMO services to biotech firms and entities with intricate requirements for injectable product development or manufacturing.
The new business unit is poised to expedite production and fulfil growth targets by facilitating the provision of its R&D, formulation, and manufacturing services to external pharmaceutical partners.
The expansion is currently underway and will position to compete on a global scale, while also broadening its client base with a variety of new products and services.
The new CDMO business unit signifies a strategic approach to optimising the value derived from research and development endeavours, as well as from each unit manufactured at Candiac plant.
It is expected to be completely by 2026.
Specifications:
Name Pharmascience
Type Expansion
Budget US$120 million
Year 2026
